Chlorogenic acid prevents ovariectomized-induced bone loss by facilitating osteoblast functions and suppressing osteoclast formation

Abstract

Osteoporosis is a usual bone disease in aging populations, principally in postmenopausal women. Anti-resorptive and anabolic drugs have been applied to prevent and cure osteoporosis and are associated to a different of adverse effects. Du-Zhong is usually applied in Traditional Chinese Medicine to strengthen bone, regulate bone metabolism, and treat osteoporosis. Chlorogenic acid is a major polyphenol in Du-Zhong. In the current study, chlorogenic acid was found to enhance osteoblast proliferation and differentiation. Chlorogenic acid also inhibits the RANKL-induced osteoclastogenesis. Notably, ovariectomy significantly decreased bone volume and mechanical properties in the ovariectomized (OVX) rats. Administration of chlorogenic acid antagonized OVX-induced bone loss. Taken together, chlorogenic acid seems to be a hopeful molecule for the development of novel anti-osteoporosis treatment.

Osteogenic mechanism of chlorogenic acid and its application in clinical practice

“…In recent years, CGA has been reported to reduce osteoclast differentiation and bone resorption. It was also shown to increase tibial mineralization and improve bone strength of the femoral backbone in in vivo experiments, which may be related to its regulation of the RANKL signaling pathway (Kuroyanagi et al, 2017;Chen et al, 2021;Ho et al, 2024). RANKL can bind to the RANK receptor on the surface of osteoblasts, thereby activating a number of major intracellular signaling pathways, including nuclear factor-κB (NF-κB), JNK, ERK, and p38 MAPK.…”

The therapeutic mechanism of Compound Lurong Jiangu Capsule for the treatment of cadmium-induced osteoporosis: network pharmacology and experimental verification

“…CLJC is an experienced formula by professor Zhang wentai of the department of orthopedics of the affiliated hospital of changchun university of traditional chinese medicine, which is a traditional chinese medicine preparation developed on the basis of the theory of traditional chinese medicine and is also a drug recommended by China Food and Drug Administration (CFDA) for the treatment of osteoporosis ( 22 ).As a prescription for bushen zhuanggu, CLJC consists of Eucommia ulmoides, Angelica sinensis, Panaxnotoginseng, Amomum villosum Lour, Zhishouwu, Leech, Cartialgenous, Chinemys reevesii, and Dried human placenta , which can significantly increase cortical bone thickness and trabecular bone width, improving osteoblast activity and promoting bone formation in ovariectomized (OVX) rats ( 23 ). At the same time, clinical studies showed that CLJC combined with other drugs can also increase the bone density and improve the bone metabolic index, which enhances the quality of life of patients ( 24 ).…”